|
|
 |
November 8, 2007 |
Now Available: Video Podcasts of MSK Report's Meeting Coverage
With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment. MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts.
ACR 2007: Visit Musculoskeletal Report's dedicated ACR 2007 page for complete coverage of the American College of Rheumatology's 71st Annual Scientific Meeting, including press conference videos.
ACR 2007: Half of RA Patients Might Reach Remission With Early, Aggressive Use of Conventional DMARDs
Measuring levels of circulating antiangiogenic factors sFlt-1 and sEng may help identify which patients with systemic lupus erythematosus (SLE) and/or antiphospholipid antibodies will develop preeclampsia...
ACR 2007: Biomarkers May Identify Risk for Preeclampsia in Lupus Pregnancies
If inflammatory arthritis is detected early and treated vigorously, remission is a possibility for 50% of patients...
CME News: Serum Uric Acid May Be Independent Risk Factor in RA Cardiovascular Disease
Elevated serum uric acid, a potentially modifiable problem, may be an independent risk factor for cardiovascular disease in patients with RA...
BioPharm Business: Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of AS in Phase III Study; Monthly Treatment Yielded Marked Improvements in Physical Function
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that more than half of patients receiving monthly subcutaneous injections of golimumab 50 mg and 100 mg experienced significant and sustained improvements in the signs and symptoms of active ankylosing spondylitis (AS), according to the phase III study (GO-RAISE trial) results...
BioPharm Business: Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Improved Articular, Skin, and Nail Manifestations in Patients With Psoriatic Arthritis in Phase III Study; Met Primary and Major Secondary Endpoints
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that patients with active psoriatic arthritis (PsA) receiving monthly subcutaneous injections of golimumab experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest phase III biologic study (GO-REVEAL trial) in PsA subjects...